The evolution of bladder cancer treatment : Improvements in clinical management, enhanced clinical outcomes, and targeting newly identified molecular alterationsBAJORIN, Dean F.Seminars in oncology. 2007, Vol 34, Num 2, pp 73-74, issn 0093-7754, 2 p.Article

Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancerBAJORIN, Dean F.Journal of clinical oncology. 2001, Vol 19, Num 18, pp 17s-20s, issn 0732-183X, SUPConference Paper

Chemotherapy for good-risk germ-cell tumorsRYAN, Charles J; BAJORIN, Dean F.Seminars in urologic oncology. 2002, Vol 20, Num 4, pp 244-250, issn 1081-0943, 7 p.Article

Advances in urologic oncology : Results progress from successful interdisciplinary researchBAJORIN, Dean F; MOTZER, Robert J; BOSL, George J et al.Journal of clinical oncology. 2006, Vol 24, Num 35, pp 5479-5481, issn 0732-183X, 3 p.Article

Chemotherapy agents in transitional cell carcinoma : The old and the newMALUF, Fernando C; BAJORIN, Dean F.Seminars in urologic oncology. 2001, Vol 19, Num 1, pp 2-8, issn 1081-0943Article

Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancerHERR, Harry W; DONAT, S. Machele; BAJORIN, Dean F et al.The Journal of urology. 2001, Vol 165, Num 3, pp 811-814, issn 0022-5347Article

Advanced Bladder Cancer : Status of First-line Chemotherapy and the Search for Active Agents in the Second-line SettingGALLAGHER, David J; MILOWSKY, Matthew I; BAJORIN, Dean F et al.Cancer. 2008, Vol 113, Num 6, pp 1284-1293, issn 0008-543X, 10 p.Article

Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meetingAPOLO, Andrea B; GROSSMAN, Herbert Barton; BAJORIN, Dean et al.Urologic oncology. 2012, Vol 30, Num 6, pp 772-780, issn 1078-1439, 9 p.Article

Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary retroperitoneal lymph node dissection for clinical stages I and IIA nonseminomatous germ cell tumorsSHEINFELD, Joel; MOTZER, Robert J; RABBANI, Farhang et al.The Journal of urology. 2003, Vol 170, Num 4, pp 1159-1162, issn 0022-5347, 4 p., 1Article

Defining optimal therapy for muscle invasive bladder cancerHERR, Harry W; DOTAN, Zohar; DONAT, S. Machele et al.The Journal of urology. 2007, Vol 177, Num 2, pp 437-443, issn 0022-5347, 7 p.Article

A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma : results of the Cancer and Leukaemia Group B 90102PHILIPS, George K; HALABI, Susan; SANFORD, Ben L et al.BJU international (Papier). 2008, Vol 101, Num 1, pp 20-25, issn 1464-4096, 6 p.Article

Overview of bladder Cancer trials in the Cancer and Leukemia Group BSMALL, Eric J; HALABI, Susan; DALBAGNI, Guido et al.Cancer. 2003, Vol 97, Num 8, pp 2090-2098, issn 0008-543X, 9 p., SUPConference Paper

Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell TumorsCARVER, Brett S; SERIO, Angel M; BAJORIN, Dean et al.Journal of clinical oncology. 2007, Vol 25, Num 35, pp 5603-5608, issn 0732-183X, 6 p.Article

Etoposide and cisplatin chemotherapy for meta good-risk germ cell tumorsKONDAGUNTA, G. Varuni; BACIK, Jennifer; BAJORIN, Dean et al.Journal of clinical oncology. 2005, Vol 23, Num 36, pp 9290-9294, issn 0732-183X, 5 p.Article

Results of retroperitoneal lymph node dissection for clinical stage I and II pure embryonal carcinoma of the testisPOHAR, Kamal S; RABBANI, Farhang; BOSL, George J et al.The Journal of urology. 2003, Vol 170, Num 4, pp 1155-1158, issn 0022-5347, 4 p., 1Article

The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular CancerCARVER, Brett S; CRONIN, Angel M; EGGENER, Scott et al.Urology (Ridgewood, NJ). 2010, Vol 75, Num 6, pp 1431-1435, issn 0090-4295, 5 p.Article

Evaluation of Lymph Node Counts in Primary Retroperitoneal Lymph Node DissectionTHOMPSON, R. Houston; CARVER, Brett S; BOSL, George J et al.Cancer. 2010, Vol 116, Num 22, pp 5243-5250, issn 0008-543X, 8 p.Article

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladderDALBAGNI, Guido; RUSSO, Paul; BOCHNER, Bernard et al.Journal of clinical oncology. 2006, Vol 24, Num 18, pp 2729-2734, issn 0732-183X, 6 p.Article

Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node DissectionTHOMPSON, R. Houston; CARVER, Brett S; BOSL, George J et al.Urology (Ridgewood, NJ). 2011, Vol 77, Num 2, pp 368-372, issn 0090-4295, 5 p.Article

Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumorsKONDAGUNTA, G. Varuni; BACIK, Jennifer; DONADIO, Alessia et al.Journal of clinical oncology. 2005, Vol 23, Num 27, pp 6549-6555, issn 0732-183X, 7 p.Conference Paper

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladderDALBAGNI, Guido; RUSSO, Paul; BAJORIN, Dean et al.Journal of clinical oncology. 2002, Vol 20, Num 15, pp 3193-3198, issn 0732-183XArticle

Clinical Trial Design for the Development of New Therapies for Nonmuscle-invasive Bladder Cancer: Report of a Food and Drug Administration and American Urological Association Public WorkshopJAROW, Jonathan P; LERNER, Seth P; O'DONNELL, Michael et al.Urology (Ridgewood, NJ). 2014, Vol 83, Num 2, pp 262-264, issn 0090-4295, 3 p.Article

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinomaMILOWSKY, Matthew I; DITTRICH, Christian; ROSENBERGG, Jonathan E et al.European journal of cancer (1990). 2014, Vol 50, Num 18, pp 3145-3152, issn 0959-8049, 8 p.Article

Activities and accomplishments of the cancer and leukemia Group B genitourinary committeeSMALL, Eric J; HALABI, Susan; KANTOFF, Phillip et al.Clinical cancer research. 2006, Vol 12, Num 11, issn 1078-0432, 3596s-3600s, 2Article

Cluster analysis of p53 and Ki67 expression, apoptosis, alpha-fetoprotein, and human chorionic gonadotrophin indicates a favorable prognostic subgroup within the embryonal carcinoma Germ Cell tumorMAZUMDAR, Madhu; BACIK, Jennifer; TICKOO, Satish K et al.Journal of clinical oncology. 2003, Vol 21, Num 14, pp 2679-2688, issn 0732-183X, 10 p.Article